Latest Oncology News

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

September 18th 2021

Kristi Rosa

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

September 18th 2021

Jessica Hergert

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

Pembrolizumab/Olaparib Combo May Improve PSA Response Regardless of HRR Mutation Status in mCRPC

September 18th 2021

Benjamin Saylor

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Pembrolizumab/Olaparib Combo Shows Promising Antitumor Activity in mCRPC

Pembrolizumab/Olaparib Combo Shows Promising Antitumor Activity in mCRPC

September 18th 2021

Janelle Hart

The combination of pembrolizumab plus olaparib produced promising antitumor activity in men with molecularly unselected docetaxel-pretreated metastatic castration-resistant prostate cancer.

Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC

Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC

September 18th 2021

Jason Harris

Poziotinib, administered once daily at 16 mg, induced a median tumor reduction of 35% in patients with treatment-naïve non–small cell lung cancer harboring HER2 exon 20 mutations, according to findings from cohort 4 of the ongoing phase 2 ZENITH20 trial.

Latest Oncology Videos

All Oncology News

Relatlimab/Nivolumab Improves TFI and PFS2 in Frontline Advanced Melanoma

September 18th 2021

Kristi Rosa

The addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.

Osimertinib/Bevacizumab Combo Does Not Improve PFS in EGFR-Mutant NSCLC

September 18th 2021

Sara Karlovitch

The combination of osimertinib and bevacizumab did not produce a superior progression-free survival benefit vs osimertinib alone in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation.

Trastuzumab Deruxtecan Impresses With Clinical Activity in HER2-Mutant NSCLC

September 18th 2021

Gina Mauro

Fam-trastuzumab deruxtecan-nxki showcased robust and durable antitumor activity in previously treated patients with HER2-mutant non–small cell lung cancer.

CRISPR/Cas9 and mRNA-Based Technology Allows for Gene Editing and Expression in CLL Cells

September 18th 2021

Caroline Seymour

CRISPR/Cas9 and mRNA-based gene editing and expression was found to be feasible in evaluating primary chronic lymphocytic leukemia cells.

COVID-19 Continues to Result in High Admission, Fatality Rates Among Patients With CLL

September 18th 2021

Kristi Rosa

COVID-19 continued to result in high admission and fatality rates among patients with chronic lymphocytic leukemia during the first 13 months of the pandemic, and although risk of severe infection was determined to be independent of age, CLL status, and treatment, being age 75 years or older was revealed to be a significant risk factor for death.

Goy Taps Into the True Potential of Precision Medicine in Oncology

September 18th 2021

Caroline Seymour

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

September 18th 2021

Brielle Benyon

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Perioperative Cabozantinib Yields Promising Results in mRCC

September 18th 2021

Sara Karlovitch

Perioperative treatment with cabozantinib induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma

Novel Immunotherapy Options Prompt Paradigm Shift in NSCLC Treatment

September 18th 2021

Courtney Marabella

A shift in the NSCLC treatment paradigm came in the form of immunotherapy, which has since seen significant progress—mostly in the past decade.

Trastuzumab Deruxtecan Elicits Encouraging Activity in Western Patients With HER2+ Gastric/GEJ Cancer

September 17th 2021

Gina Mauro

Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate in Western patients with HER2-positive gastric/gastroesophageal junction cancer.

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

September 17th 2021

Wayne Kuznar

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Nivolumab/Ipilimumab Demonstrates Superior Likelihood of Long-Term Survival Vs Sunitinib in Advanced RCC

September 17th 2021

Conor Killmurray

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

Toripalimab/Chemo Combo Elicits Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma

September 17th 2021

Brittany Lovely

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Promising Clinical Activity Showcased With Olaparib Plus Bipolar Androgen Therapy in Prostate Cancer

September 17th 2021

Jason Broderick

Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.

Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib, Improves pCR, EFS in TNBC

September 17th 2021

Gina Mauro

The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide significantly improved pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer.

See All News